Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (2015) 3.25

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis (2011) 2.56

Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS (2009) 1.93

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63

BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res (2003) 1.45

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr (2014) 1.43

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr (2013) 1.31

Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother (1995) 1.28

Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm (2009) 1.28

Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother (1998) 1.26

Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res (2006) 1.24

Fractures after antiretroviral initiation. AIDS (2012) 1.21

Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab (1999) 1.19

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun (2010) 1.13

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr (2016) 1.08

Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS (2003) 1.06

Bone health and human immunodeficiency virus infection. Pharmacotherapy (2013) 0.99

Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med (2005) 0.98

Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol (2008) 0.97

In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob Agents Chemother (2011) 0.96

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res (2015) 0.90

HIV inhibitors: problems and reality. Ann N Y Acad Sci (2001) 0.88

Evaluation of adverse events associated with antiretroviral therapy and the relationship to treatment adherence. Int J Clin Pharmacol Ther (2013) 0.83

A unified model for bone-renal mineral and energy metabolism. Curr Opin Pharmacol (2015) 0.80

HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. Antiviral Res (2007) 0.80

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. Antimicrob Agents Chemother (2015) 0.78

Tenofovir-related nephrotoxicity: an ongoing clinical challenge. Am J Health Syst Pharm (2013) 0.77